DK2154147T3 - Trunkeret L1-protein af human papillomavirus 16 - Google Patents

Trunkeret L1-protein af human papillomavirus 16 Download PDF

Info

Publication number
DK2154147T3
DK2154147T3 DK08748431.7T DK08748431T DK2154147T3 DK 2154147 T3 DK2154147 T3 DK 2154147T3 DK 08748431 T DK08748431 T DK 08748431T DK 2154147 T3 DK2154147 T3 DK 2154147T3
Authority
DK
Denmark
Prior art keywords
leu
thr
val
pro
gly
Prior art date
Application number
DK08748431.7T
Other languages
English (en)
Inventor
Ying Gu
Shaowei Li
Minxi Wei
Yangling Xian
Wenxin Luo
Ningshao Xia
Original Assignee
Beijing Wantai Biological Pharmacy Entpr Co Ltd
Univ Xiamen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Wantai Biological Pharmacy Entpr Co Ltd, Univ Xiamen filed Critical Beijing Wantai Biological Pharmacy Entpr Co Ltd
Application granted granted Critical
Publication of DK2154147T3 publication Critical patent/DK2154147T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (13)

1. Fremgangsmåde til fremstilling af et L1-protein af Fluman Papillomavirus Type 16 (HPV 16), som er i stand til at samle sig i FIPV 16-viruslignende partikler, hvilken fremgangsmåde omfatter: a) eksprimering af et gen, der koder HPV 16 L1-proteinet i E. coli under brug af ekspressionsvektor pTO-T7, b) opbrydning af E. coli, som har eksprimeret HPV 16 L1-proteinet, i en opløsning med et saltkoncentration fra 100mM til 600mM og isolering af det ovenpå-flydende, c) sænkning af saltkoncentrationen af det ovenpåflydende af b) fra 100mM til 0 inkl. ved anvendelse af vand eller en svag saltopløsning, og opsamling af et udfældningsprodukt, d) genopløsning af udfældningsproduktet af c) i en opløsning med en saltkoncentration fra 150mM til 2500 mM, tilsætning af et reduktionsmiddel til det og derefter isolering af resulterende opløsning, hvori opløsningen indeholder HPV 16 L1-proteinet med en renhed på mindst 50%, hvori HPV 16 L1 -proteinet mangler de første 30 N-terminale aminosyrer, og hvori saltet er valgt fra gruppen bestående af NaCI, KCI, NH4CI og (NH4)2S04.
2. Fremgangsmåde ifølge krav 1, yderligere omfattende: e) yderligere rensning af HPV 16 L1-protein ved kromatografi, og f) fjernelse af reduktionsmidlet fra HPV 16 L1-proteinet fremskaffet i e).
3. Fremgangsmåde ifølge krav 1, hvori HPV 16 L1-proteinet består af SEQ ID NO: 6.
4. HPV 16 viruslignende partikel (VLP) bestående af det rensede protein frembragt i E. coli og fremskaffet ved fremgangsmåden ifølge krav 2.
5. HPV 1 6 VLP ifølge krav 4, hvori HPV 16 L1 -proteinet består af SEQ ID NO:6.
6. HPV 16 viruslignende partikel (VLP) bestående af et HPV 16 L1-protein, som er frembragt i E. coli, og hvis aminosyresekvens er SEQ ID NO:6.
7. Vaccine til forebyggelse af livmoderhalskræft, omfattende: HPV16 VLP ifølge ethvert af krav 4-6 og bærere eller excipienser for vacciner.
8. Vaccine ifølge krav 7, yderligere omfattende mindst en HPV VLP valgt fra gruppen bestående af VLP’er af HPV-typer 6, 11, 18, 31, 33, 45, 52 og 58.
9. Vaccine ifølge krav 7, yderligere omfattende HPV 18 VLP omfattende et protein, hvis aminosyresekvens er SEQ ID No: 9, HPV 6 VLP omfattende et protein, hvis aminosyresekvens er SEQ ID No: 10, og HPV 11 VLP omfattende et protein, hvis aminosyresekvens er SEQ ID No: 11.
10. Anvendelse af HPV 16 VLP ifølge ethvert af krav 4-6 ved fremstilling af en vaccine til forebyggelse af livmoderhalskræft.
11. HPV 16 VLP ifølge ethvert af krav 4-6 eller vaccine ifølge ethvert af krav 7-9 til anvendelse ved forebyggelse af livmoderhalskræft.
12. Fremgangsmåde til fremstilling af en vaccine til forebyggelse af livmoderhalskræft, omfattende blanding af HPV 16 VLP ifølge ethvert af krav 4-6 med bærere eller excipienser for vacciner.
13. Fremgangsmåde ifølge krav 12, omfattende blanding af HPV 16 VLP ifølge ethvert af krav 4-6, og en eller flere VLP’er valgt fra gruppen bestående af VLP’er af HPV typer 6, 11, 18, 31, 33, 45, 52 og 58, med bærere eller excipienser for vacciner.
DK08748431.7T 2007-04-29 2008-04-29 Trunkeret L1-protein af human papillomavirus 16 DK2154147T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710097762 2007-04-29
CN200810008761 2008-01-23
PCT/CN2008/000872 WO2008134934A1 (en) 2007-04-29 2008-04-29 A truncated l1 protein of human papillomavirus 16

Publications (1)

Publication Number Publication Date
DK2154147T3 true DK2154147T3 (da) 2015-12-07

Family

ID=39943110

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08748431.7T DK2154147T3 (da) 2007-04-29 2008-04-29 Trunkeret L1-protein af human papillomavirus 16

Country Status (7)

Country Link
US (1) US9428555B2 (da)
EP (1) EP2154147B1 (da)
CN (1) CN101293918B (da)
BR (1) BRPI0811016B1 (da)
DK (1) DK2154147T3 (da)
HK (1) HK1124868A1 (da)
WO (1) WO2008134934A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2147926T3 (da) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Trunkerede humane papillomavirus type 18 L1 proteiner
BRPI0811016B1 (pt) 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
US8748127B2 (en) * 2007-05-29 2014-06-10 Xiamen University Truncated L1 protein of human papillomavirus type 6
IN2013CN00536A (da) * 2010-07-02 2015-07-03 Univ Xiamen
CN102229660B (zh) 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
CN102747047B (zh) * 2012-02-28 2016-03-23 厦门大学 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法
CN105039358B (zh) * 2013-12-03 2020-02-28 北京康乐卫士生物技术股份有限公司 58型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106795518A (zh) * 2014-06-19 2017-05-31 科罗拉多大学董事会，法人 人类乳头瘤病毒构建体
WO2016104923A1 (ko) * 2014-12-26 2016-06-30 아이진 주식회사 인유두종 바이러스의 바이러스 유사 입자 제조방법
CN107184973A (zh) * 2016-03-15 2017-09-22 中国医学科学院基础医学研究所 一种复合疫苗佐剂及其应用
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN106884017B (zh) * 2016-12-28 2024-03-26 中国食品药品检定研究院 用于包装柯萨奇病毒b5假病毒的重组表达质粒、假病毒、试剂盒和方法
CN109251235B (zh) * 2017-07-14 2021-04-27 厦门大学 一种人乳头瘤病毒16型l1蛋白的突变体
CN110551183A (zh) * 2018-06-04 2019-12-10 厦门大学 一种人乳头瘤病毒39型l1蛋白的突变体
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
CN114716561B (zh) 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN114716560B (zh) 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途
CN114292321B (zh) * 2021-12-30 2023-06-16 重庆澳龙生物制品有限公司 可溶性表达eg95蛋白及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE494005T1 (de) * 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichem papillomaviren hüllprotein und virus-ähnlichen teilchen
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
IL113817A (en) 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
DE122007000093I1 (de) 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US6908615B1 (en) * 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
ATE324436T1 (de) 1998-08-14 2006-05-15 Merck & Co Inc Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
AU3730600A (en) * 1999-03-18 2000-10-04 Xiaojiang Chen Compositions preparations and uses of human papillomavirus l1 protein
DE10059630A1 (de) 2000-12-01 2002-06-06 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von durch humanen Papillomavirus-Typ 18-hervorgerufenem Tumor
AP2004003021A0 (en) 2001-08-31 2004-06-30 Univ Cape Town Vectors, constructs and transgenic plants for HPV-11 and HPV-16 L1 capsid protein.
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003228816A1 (en) 2002-05-02 2003-11-17 Boyce Thompson Institute For Plant Research, Inc. Production of papillomavirus vaccines in plants
CN1293093C (zh) * 2002-08-30 2007-01-03 马润林 乳头瘤病毒衣壳蛋白的原核制备和应用
EP1572233B1 (en) * 2002-12-20 2011-03-30 GlaxoSmithKline Biologicals s.a. Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CN1683010A (zh) 2005-02-06 2005-10-19 哈尔滨医科大学 人乳头瘤病毒型双价病毒样颗粒混合蛋白抗原及构建方法
CN100392084C (zh) 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
CN101153280B (zh) 2006-09-29 2015-08-19 厦门大学 从原核生物中纯化人乳头瘤病毒晚期蛋白l1的方法
WO2008112125A1 (en) 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
BRPI0811016B1 (pt) 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
DK2147926T3 (da) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Trunkerede humane papillomavirus type 18 L1 proteiner
EP2910566B1 (en) 2007-05-29 2016-07-13 Xiamen University A truncated L1 protein of human papillomavirus 11

Also Published As

Publication number Publication date
EP2154147A4 (en) 2011-11-02
US20100255031A1 (en) 2010-10-07
EP2154147A1 (en) 2010-02-17
EP2154147B1 (en) 2015-10-07
BRPI0811016A2 (pt) 2015-01-27
BRPI0811016B1 (pt) 2021-09-21
US9428555B2 (en) 2016-08-30
CN101293918A (zh) 2008-10-29
CN101293918B (zh) 2013-03-27
WO2008134934A1 (en) 2008-11-13
HK1124868A1 (en) 2009-07-24

Similar Documents

Publication Publication Date Title
DK2154147T3 (da) Trunkeret L1-protein af human papillomavirus 16
US10537629B2 (en) Truncated L1 protein of human papillomavirus type 11
EP2716653B1 (en) Truncated human papillomavirus type 33 protein l1
US9745351B2 (en) Truncated L1 protein of human papillomavirus type 6
EP2589604B1 (en) Truncated l1 protein of human papillomavirus type 52
DK2147926T3 (da) Trunkerede humane papillomavirus type 18 L1 proteiner
US9738691B2 (en) Truncated L1 protein of human papillomavirus type 58